Research Article
Inhibitory Effect of Chemical Constituents Isolated from
Artemisia iwayomogi on Polyol Pathway and Simultaneous
Quantification of Major Bioactive Compounds
Yoon Kyoung Lee, Eun Young Hong, andWan KyunnWhang
Pharmaceutical Botany Laboratory, College of Pharmacy, Chung-Ang University, Heukseok-dong, Dongjak-gu,
Seoul 156-756, Republic of Korea
Correspondence should be addressed to Wan Kyunn Whang; whang-wk@cau.ac.kr
Received 28 February 2017; Revised 27 March 2017; Accepted 30 March 2017; Published 23 April 2017
Academic Editor: Sung-Hoon Kim
Copyright Â© 2017 Yoon Kyoung Lee et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Blocking the polyol pathway plays an important role preventing diabetic complications. Therefore, aldose reductase (AR) and
advanced glycation endproducts (AGEs) formation has significant effect on diabetic complications. Artemisia iwayomogi has long
been used as treatment of various diseases in Korea. However, no literatures have reported on AR and AGEs formation inhibitory
activities of A. iwayomogi. For these reasons, we aimed to assess that A. iwayomogi had potential as anti-diabetic complications
agents. We led to isolation of two coumarins (1 and 2), nine flavonoids (3â€“11), five caffeoylquinic acids (12â€“16), three diterpene
glycosides (17â€“19), and one phenolic compound (20) from A. iwayomogi. Among them, hispidulin (4), 6-methoxytricin (6),
arteanoflavone (7), quercetin-3-gentiobioside (10), 1,3-di-O-caffeoylquinic acid (13), and suaviosideA (18) were first reported on the
isolation fromA. iwayomogi. Not only two coumarins (1 and 2), nine flavonoids (3â€“11), and five caffeoylquinic acids (12â€“16) but also
extracts showed significant inhibitor on AR and AGEs formation activities. We analyzed contents of major bioactive compounds
in Koreaâ€™s various regions of A. iwayomogi. Overall, we selected Yangyang, Gangwon-do, from June, which contained the highest
amounts of bioactive compounds, as suitable areas for cultivating A. iwayomogi as preventive or therapeutic agent in the treatment
of diabetic complications.
1. Introduction
Aldose reductase (AR) belongs to the aldo-keto reductase
family. It is the first and rate-controlling enzyme in the polyol
pathway that reduces glucose to sorbitol using nicotinamide
adenine dinucleotide 2ó¸€ -phosphate (NADPH) as a cofactor
[1, 2]. Although blood sugar is high, the polyol pathway
converts the excess glucose into sorbitol and then fructose.
This accumulation of sorbitol and fructose has been demon-
strated to be responsible for diabetic complications, including
nephropathy, cataracts, neuropathy, and retinopathy [3, 4].
In particular, sorbitol is implicated in the pathogenesis of
sugar cataracts, while the accumulation of fructose induces
the formation of advanced glycation endproducts (AGEs),
which are strongly implicated in diabetic complications and
Alzheimerâ€™s disease [5]. Therefore, research on AR and
AGEs formation inhibition is on the rise. There is a wide
range of literature demonstrating that the developments of
AR and AGEs formation are blocked by natural sources,
especially plants that have an enormous content of bioactive
compounds [6, 7].
Artemisia iwayomogi, locally called haninjin or dowijigi,
is a member of the Compositae family and a perennial herb
mainly found in Korea. A. iwayomogi has long been used in
Korea in vegetables and foods such as tea, rice cake, and soup
and also used for the treatment of various diseases including
hepatitis, inflammation, and immune-related diseases as a
protection for the liver, and a diuretic [8â€“10]. Previous
studies have reported the isolation of scopoletin, esculetin 6-
methylether, scopolin, ğ›½-sitosterol, chlorogenic acid, quebra-
chitol, essential oils, fatty acids, sesquiterpene lactones, and
flavonoids in A. iwayomogi [11â€“14]. Among them, scopolin
modulated the expression of obesity-associated genes and
was shown to have pharmacological effects on obesity, fatty
Hindawi
BioMed Research International
Volume 2017, Article ID 7375615, 12 pages
https://doi.org/10.1155/2017/7375615
2 BioMed Research International
liver, and diabetes [15]. A. iwayomogi has also demonstrated
various biological activities. For example, methanol extracts
of A. iwayomogi were shown to act as a scavenger of pero-
xynitrile, a compound involved in inducing or maintain-
ing many diseases, including inflammation and aging [16].
Methanol extract of A. iwayomogi also inhibits nitric oxide
in the production of lipopolysaccharide activated macro-
phages [17]. In other studies, a water-soluble carbohydrate
fraction from A. iwayomogi suppressed spontaneous or 2,3,
7,8-tetrachlorodibenzo-p-dioxin-induced apoptotic death of
mouse thymocytes by downregulating Fas gene expression
[18, 19]. A water-soluble carbohydrate fraction from A. iway-
omogi also repressed pulmonary eosinophilia and Th2-type
cytokine production in ovalbumin-induced allergic asthma
via downregulation of TNF-ğ›¼ expression in the lungs [20],
showed antitumor, immunomodulating activities [9], and
modulated the functional differentiation of bone marrow-
derived dendritic cells [21].
However, A. iwayomogiâ€™s ability to inhibit AR and AGEs
formation has never been previously studied. We investi-
gated various components found in A. iwayomogi and their
inhibitory activities on AR and AGEs formation. Our study
also determined the bioactive compounds present in A.
iwayomogi by region in Korea using an HPLC-PAD. Based
on our study, we selected suitable areas for cultivating A.
iwayomogi as medicinal foods.
2. Materials and Methods
2.1. Plant Materials. The aerial parts of A. iwayomogi
were purchased from Kyung-Dong market, Seoul, Korea.
Moreover, the aerial parts of A. iwayomogi were collected
from Seoul, Gyeongii-do, Chungcheongbuk-do, Jeollabuk-
do, Jeollanam-do, Gyeongsangbuk-do, Gyeongsangnam-do,
Gangwon-do, and Jeju-do Korea for analysis. Professor
Whang Wan Kyunn identified A. iwayomogi which was
bought inKyung-Dongmarket and collected in various speci-
mens.
2.2. Instruments and Reagents. Toluene, ethyl formate, chlo-
roform (CHCl3), ethyl acetate (EtOAc), methanol (MeOH),
ethanol (EtOH), distilled water, and formic acid were
used as the open column chromatography and thin layer
chromatography. Open column chromatography was used
with Amberlite gel (Nippon Rensui Co., Japan), silica gel
(200âˆ¼400mesh; Merck Co., Germany), Sephadex LH-20
(25â€“100 ğœ‡m; Pharmacia, Sweden), MCI CHP 20P (Supelco,
USA), and ODS gel (400â€“500mesh; Waters, USA). Thin
layer chromatography was conducted with a Kiesel gel 60
F254 (Merck Co., Darmstadt, Germany) and plates (silica gel,
0.25mm layer on aluminum sheets), and compounds were
profiled by spraying with 10% H2SO4 in EtOH, followed
by heating to 110âˆ˜C. Dimethyl sulfoxide-d6 (DMSO-d6),
methanol-d6 (CD3OD), and pyridine-d6 were used as the
NMR solution. MS was performed using fast atom bombard-
ment mass spectrometry (FAB-MS) conducted using a JEOL
JMS-600W (Tokyo, Japan) mass spectrometer, a Q-TOF
Synapt G2 apparatus (Waters, Milford, Massachusetts, USA)
equipped with electrospray ionization (ESI), and electrospray
ionization hybrid linear trap-quadruple-orbitrap (ESI/LTQ-
Orbitrap) using an Ultimate 3000 RSLC (Thermo, Germany).
1H and 13C-nuclear magnetic resonance (NMR) spectra were
conducted at 600MHz and 150MHz, respectively, with a Var-
ianGemini 2000 (USA) spectrometer using tetramethylsilane
(TMS) as an internal standard. Chemical shifts are expressed
as parts per million (ppm) on the ğ›¿ scale, and coupling
constants (J) are showed in Hertz. HPLC was conducted
using Empower Pro 2.0 software and determination was per-
formed using a Waters 2695 system pump with a Waters 996
Photodiode array detector (USA). The separation column
was a Waters Sunfire column C18 (4.6 Ã— 250mm, 5 ğœ‡m).
HPLC-grade solvents such as acetonitrile (ACN), methanol
(MeOH), and distilled water (H2O) were purchased from J.
T. Baker (Phillipsburg, PA, USA). HPLC-grade formic acid
and dimethyl sulfoxide (DMSO) were obtained from DEA-
JUNG Chemical (Siheung, Gyeonggi, Korea). Reagents and
solvents including dl-glyceraldehyde, potassium phosphate
buffer, nicotinamide adenine dinucleotide 2ó¸€ -phosphate (ğ›½-
NADPH), sodium phosphate buffer, sodium azide, 3,3-
tetramethyleneglutaric acid (TMG), bovine serum albumin,
aminoguaidine (AG), glucose, and fructose were purchased
from Sigma-Aldrich (St. Louis, MO, USA).
2.3. Extraction, Fractionation, and Isolation from A. iway-
omogi. The dried and powdered aerial parts of A. iwayomogi
(5 kg) were extracted with 50% EtOH (20 L Ã— 3) at room tem-
perature. The filtrate was concentrated to dryness (692.1 g)
in vacuo, suspended in water (H2O), and then partitioned
using CHCl3 (97.6 g). After partitioning, the water fraction
(456.7 g) was chromatographed on a Amberlite XAD-2 using
water, 30% methanol, 60% methanol, and 100% methanol.
The result yielded water (240 g), 30%methanol (92.18 g), 60%
methanol (49.31 g), and 100% methanol (70.24 g) fractions.
The CHCl3 fraction (97.6 g) was chromatographed with
a silica gel solvent system to increase the elution power of
CHCl3 :MeOH (20 : 1 to 0 : 100) and yielded ten subfractions.
Subfraction 2 (25.62 g) was separated using Sephadex LH-20
column chromatographywith 50%MeOH to obtain fractions
2-1âˆ¼2-11. Compound 1 (1.16 g) was isolated from fraction 2-2.
In addition, separation of subfraction 2-3 (6.39 g) using an
MCI gel with 50% MeOH solvent system yielded fourteen
fractions. Subfraction 2-3-10 led to isolation of compound
3 (34.4mg). Fraction 2-3-6 (632.5mg) was separated using
ODS column chromatography with a 60% MeOH elution
solvent system to collect fractions 2-3-6-1âˆ¼2-3-6-4. Com-
pound 5 (97.5mg) was isolated from subfraction 2-3-6-2 by
recrystallization, and then a portion of subfraction 2-3-6-2
(324.2 mg) was used on a Sephadex LH-20 (50% MeOH),
to yield compound 6 (13.2mg). Subfraction 2-3-9 (448.4
mg) was separated using ODS (60% MeOH), MCI (50%
MeOH), and Sephadex LH-20 (40% EtOH), which yielded
compound 7 (17.5mg). Fraction 3 (2.38 g) was applied to a
Sephadex LH-20 column chromatography with a gradient
solvent system of 50% to 100% MeOH and yielded fourteen
fractions. Fraction 3-9 (96.8mg) was separated using ODS
column chromatography with 70% MeOH, which obtained
BioMed Research International 3
six fractions (3-9-1âˆ¼3-9-6). Subfraction 3-9-3 (20mg) was
chromatographed on a Sephadex LH-20 using 50%MeOH to
yield compound 4 (19.9mg).
A portion of the 100% MeOH fraction (15 g) was sepa-
rated using a Sephadex LH-20 column chromatography with
a gradient elution solvent system of 20% to 100% MeOH
to give eighteen subfractions. Subfraction 3 (0.93 g) was
applied to ODS column chromatography using a 10%MeOH
solvent system to yield compound 12 (37.9mg). Subfraction
16 (0.99 g) was separated using a ODS column chromatog-
raphy with 20% MeOH, and ten fractions (16-1âˆ¼16-10) were
collected. Fraction 16-6 (134.3mg) led to the isolation of
compound 14 (70.0mg) by recrystallization. Fraction 16-5
(395.7mg) was separated by a Sephadex LH-20 using an
eluent of 40%EtOH, which yielded compounds 15 (272.2mg)
and 16 (72.2mg).
The 60% MeOH fraction (49.31 g) was separated using
a Sephadex LH-20 column chromatography with a gradient
of 40% MeOH to 100% MeOH, which yielded twelve sub-
fractions. Subfraction 1 (6.7 g) was separated by an MCI gel
using a 50% MeOH to 100% MeOH solvent system, which
yielded fifteen fractions (1-1âˆ¼1-15). Fractions 1-8 (331.6 mg),
1-9 (101.6mg), and 1-10 (157.5mg) were isolated by recrys-
tallization to yield compounds 17 (32.7mg), 18 (9.2mg),
and 19 (28.6mg), respectively. Subfraction 3 (923.4mg) was
separated using an ODS column chromatography, and seven
fractions (3-1âˆ¼3-7) were collected after elution with 40%
MeOH. Fraction 3-3 (140.4mg) was separated by MCI col-
umn chromatography using an eluent of 50%MeOH, leading
to the isolation of compound 20. Subfraction 5 (1.48 g) was
separated using an MCI gel and eluted with 50% MeOH,
which yielded compound 8 (281.7mg). A portion of fraction
5-3 (166.2mg) was applied to an MCI gel and eluted with
40% MeOH. Fraction 5-3-3 (106mg) was separated by a
Sephadex LH-20 column chromatography using an eluent of
50% EtOH to yield compounds 10 (23.1mg) and 11 (36.8mg).
Subfraction 7 (806.2mg) and subfraction 8 (3. 77 g) were
chromatographed on an MCI gel using 40% MeOH, to give
fractions 7-1âˆ¼7-10 and 8-1âˆ¼8-12, respectively. Compound 9
(76.6mg) was isolated from fraction 7-4 (108.8mg) using a
Sephadex LH-20 eluting with 50% EtOH. Subfraction 8-2
(3.77 g) was separated using a Sephadex LH-20 eluting with
40% MeOH. Fraction 8-2-3 was applied to a Sephadex LH-
20 column chromatography using 20% EtOH, which yielded
compound 13 (111.1mg).
A portion of the 30% MeOH fraction (14 g) was chro-
matographed on a Sephadex LH-20 column chromatography
using a solvent system of 20% MeOH to 100% MeOH,
which yielded seven subfractions. Fraction 2 (7.12mg) was
separated using an ODS column chromatography, and fifteen
fractions (2-1âˆ¼2-15) were collected after elution with 5%
MeOH. Subfraction 2-6 was applied to an MCI gel using 5%
EtOH, which yielded compound 2 (171.4mg).
2.4. Measurement of AR Inhibitory Activity. Rat lenses (one
lens per 0.5mL sodium buffer) were obtained from Sprague-
Dawley rats (weighing 250âˆ¼280 g). The rat lenses were
homogenized in 0.1M sodium phosphate buffer (pH 6.2) and
centrifuged at 10,000 rpm (4âˆ˜C, 20min). After centrifuga-
tion, the supernatant was used as an enzyme. AR activity
was spectrophotometrically determined by measuring the
decrease in the absorption of ğ›½-NADPH at 340 nm for a
4min period using dl-glyceraldehydes as substrates [22].The
assay mixture contained 1.6mM ğ›½-NADPH, 0.1M potassium
phosphate buffer (pH 7.0), AR homogenate, 4M ammonium
sulfate, 0.025M dl-glyceraldehyde, and the sample in 100%
DMSO. The total volume of the assay mixture was 0.3mL
and the reaction was performed in a 96-well plate. 3,3ó¸€ -
Tetramethylene glutaric acid (TMG), a typical AR inhibitor,
was used as a positive control.
2.5. Measurement of AGEs Formation Inhibitory Activity.
Inhibition of AGEs formation was determined by an assay
containing bovine serum albumin (10mg/mL) in 50mM
phosphate buffer (pH 7.4) with 0.02% sodium azide, to which
0.4M fructose and glucose was added. The assay mixture
was incubated at 60âˆ˜C for 2 days. After incubating, the
reaction was measured on Fluorescence in a 96-black-well
plate (excitation wavelength 350 nm, emission wavelength
450 nm) [23]. Aminoguaidine (AG) was used as a positive
control.
2.6. For AR and AGEs Formation Inhibition Assays, the
Activity Was Calculated. Inhibition (%): (Ac âˆ’ As/Ac) Ã— 100.
In AR inhibition activity, Ac is absorbance of control and
As is absorbance of samples. In AGEs formation inhibition
activity, Ac is fluorescence of control and As is fluores-
cence of samples. IC50 is the concentration of inhibitor that
gives a 50% inhibition in enzyme activity. IC50 values were
calculated from the least-squares regression line of the log
of concentration plotted against residual activity. All assays
were performed in triplicate. Data was presented as mean Â±
standard deviation (SD).
2.7. Sample Preparation for HPLC. Samples of A. iwayomogi
taken from the various regions in Korea and Yangyang,
Gangwon-do, monthly between June and October were dis-
solved in 50% EtOH (20mg/mL). The resulting solution was
filtered with a 0.45 ğœ‡m syringe filter. The resulting solution
was used for HPLC analysis.
2.8. HPLC Conditions. AWaters Sunfire column C18 (4.6 Ã—
250mm, 5 ğœ‡m)was used for the determination of compounds
1, 2, 8, 10, 11, 12, 14, and 15.Themobile phase consisted of 0.1%
formic acid (solvent A) and ACN (solvent B). The gradient
solvent system was solvents A and B (85 : 15) and increased
in linear gradients to 84 : 16 for 5min, to 72 : 28 for 5min,
then to 69 : 31 for 5min, and finally to 40 : 60 for 5min. The
injection volumewas 10 ğœ‡L and the flow rate was 0.9mL/min.
TheUV spectra were recorded at 330 nm for quantification of
compounds. All injections were performed in triplicate.
2.9. Calibration Curve. Stock solutions of compounds 1, 2, 8,
10, 11, 12, 14, and 15 in 50% EtOH were prepared in several
concentrations. Calibration curves of the eight standards
were calculated using concentration (ğ‘‹, ğœ‡g/mL), peak area
4 BioMed Research International
(ğ‘Œ), and mean value (ğ‘› = 3) Â± standard deviation. Contents
of the analyte solutions were then determined from the
calibration curves.
2.10. Determination of Limit of Detection (LOD) and Limit of
Quantification (LOQ). Quantification of the HPLC method
for compounds 1, 2, 8, 10, 11, 12, 14, and 15 as a standard
compound was determined by LOD and LOQ. The LOD
and LOQ were defined as detectable concentration of the
compound with a signal to noise (ğ‘†/ğ‘) ratio of â‰¥3.3 and
â‰¥10, respectively. The percent recovery was evaluated by
calculating the ratio of the amount detected versus the
amount added. The quantity of analysis was subsequently
obtained from the calibration curve.
3. Results
3.1. Identification of Compounds 1â€“20 Isolated from A.
iwayomogi. Chromatographic separation of the 50% EtOH
extraction from A. iwayomogi led to the isolation of
two coumarins (1 and 2), nine flavonoids (3â€“11), five
caffeoylquinic acids (12â€“16), three diterpene glycosides
(17â€“19), and one phenolic compound (20) (Figure 1). Com-
pounds 1â€“20 isolated from A. iwayomogi were identified
as scopoletin (1) [11, 24], scopolin (2) [11, 24], genkwanin
(3) [11], hispidulin (4) [25], jaceosidin (5) [11, 26], 6-
methoxytricin (6) [26], arteanoflavone (7) [27], patuletin-
3-O-glucoside (8) [28], isoquercetin (9) [24, 29], quercetin-
3-gentiobioside (10) [29], rutin (11) [30], 3-O-caffeoylquinic
acid (12) [24], 1,3-di-O-caffeoylquinic acid (13) [31], 3,4-di-
O-caffeoylquinic acid (14) [32], 3,5-di-O-caffeoylquinic acid
(15) [24, 32], 3,5-di-O-caffeoylquinic acid methyl ester (16)
[32], iwayoside A (17) [33], suavioside A (18) [34], sugero-
side (19) [34], and 2,4-dihydroxy-6-methoxyacetophenone
4-O-ğ›½-d-glucopyranoside (20) [11] by comparison with the
spectroscopic data (1H-NMR, 13C-NMR, and MS) from the
literature.
Compound 1: C10H8O4; Q-TOF-MS m/z: 193.0490
[M+H]+; 1H-NMR (600 MHz, DMSO-d6) ğ›¿: 7.93 (1H, d, J =
9.6Hz, H-4), 7.24 (1H, s, H-5), 6.81 (1H, s, H-8), 6.25 (1H, 3,
J = 9.0Hz, H-3), 3.85 (3H, s, 6-OMe); 13C-NMR (150MHz,
DMSO-d6) ğ›¿: 162.5 (C-2), 152.8 (C-7), 151.3 (C-9), 147.0
(C-6), 146.3 (C-4), 113.5 (C-3, 10), 112.4 (C-5), 104.5 (C-8),
57.8 (6-OMe).
Compound 2: C16H18O9; Q-TOF-MS m/z: 353.0869
[Mâˆ’H]âˆ’; 1H-NMR (600 MHz, DMSO-d6): 8.00 (1H, d, J =
9.0Hz, H-4), 7.33 (1H, d, J = 1.8Hz, H-5), 7.19 (1H, s, H-8),
6.36 (1H, 3, J = 9.0Hz, H-3), 5.12 (1H, d, J = 7.2Hz, Glc H-1),
3.86 (3H, s, 6-OMe); 13C-NMR (150MHz, DMSO-d6): 161.0
(C-2), 150.2 (C-7), 147.2 (C-9), 146.3 (C-6), 144.6 (C-4), 113.7
(C-3), 112.7 (C-10), 110.0 (C-5), 103.4 (C-8), 100.0 (Glc C-1),
77.4 (Glc C-3), 76.9 (Glc C-5), 73.3 (Glc C-2), 69.9 (Glc C-4),
60.9 (Glc C-6), 56.4 (6-OMe).
Compound 3: C16H12O5; ESI/LTQ-Orbitrap-MS m/z:
285.08 [M+H]+; 1H-NMR (600MHz, DMSO-d6): 12.93 (5-
OH), 7.96 (2H, d, J = 9.0Hz, H-2ó¸€ , 6ó¸€ ), 6.94 (2H, d, J = 9.0Hz,
H-3ó¸€ , 5ó¸€ ), 6.84 (1H, s, H-3), 6.77 (1H, s, H-8), 6.37 (1H, s, H-6),
3.87 (3H, s, 7-OMe); 13C-NMR (150MHz, DMSO-d6): 182.3
(C-4), 165.5 (C-7), 164.5 (C-2), 161.8 (C-4ó¸€ ), 161.6 (C-9), 157.6
(C-5), 133.5 (C-3), 128.9 (C-2ó¸€ , 6ó¸€ ), 121.4 (C-1ó¸€ ), 116.4 (C-3ó¸€ , 5ó¸€ ),
103.9 (C-10), 98.7 (C-6), 93.5 (C-8), 56.5 (7-OMe).
Compound 4: C16H12O6; ESI/LTQ-Orbitrap-MS m/z:
301.07 [M+H]+; 1H-NMR (600MHz, DMSO-d6): 13.04 (5-
OH), 7.88 (2H, d, J = 8.4Hz, H-2ó¸€ , 6ó¸€ ), 6.90 (2H, d, J = 8.4Hz,
H-3ó¸€ , 5ó¸€ ), 6.72 (1H, s, H-3), 6.55 (1H, s, H-8), 3.73 (3H, s, 6-
OMe); 13C-NMR (150MHz, DMSO-d6): 182.3 (C-4), 164.0
(C-2), 161.4 (C-4ó¸€ ), 157.8 (C-7), 153.1 (C-5), 152.7 (C-9), 131.7
(C-6), 128.7 (C-2ó¸€ , 6ó¸€ ), 121.5 (C-1ó¸€ ), 116.2 (C-3ó¸€ , 5ó¸€ ), 104.3 (C-3),
102.7 (C-10), 94.6 (C-8), 60.2 (6-OMe).
Compound 5: C17H14O7; ESI/LTQ-Orbitrap-MS m/z:
331.08 [M+H]+; 1H-NMR (600MHz, DMSO-d6): 13.06 (5-
OH), 7.53 (2H, s, H-5ó¸€ , 6ó¸€ ), 6.91 (1H, d, J = 9.0Hz, H-2ó¸€ ), 6.86
(1H, s, H-3), 6.58 (1H, s, H-8), 3.88 (3H, s, 6-OMe), 3.74 (3H, s,
3ó¸€ -OMe); 13C-NMR (150MHz, DMSO-d6): 182.5 (C-4), 164.1
(C-2), 158.1 (C-7), 153.1 (C-9), 152.9 (C-5), 151.2 (C-4ó¸€ ), 148.4
(C-3ó¸€ ), 131.9 (C-6), 121.9 (C-1ó¸€ ), 120.7 (C-6ó¸€ ), 116.2 (C-5ó¸€ ), 110.6
(C-2ó¸€ ), 104.3 (C-10), 103.1 (C-3), 94.8 (C-8), 60.3 (6-OMe),
56.4 (3ó¸€ -OMe).
Compound 6: C18H16O8; ESI/LTQ-Orbitrap-MS m/z:
361.09 [M+H]+; 1H-NMR (600MHz, DMSO-d6): 13.04 (5-
OH), 7.29 (2H, s, H-2ó¸€ , 6ó¸€ ), 6.93 (1H, s, H-3), 6.64 (1H, s, H-
8), 3.86 (3H, s, 6-OMe), 3.73 (6H, s, 3ó¸€ , 5ó¸€ -OMe); 13C-NMR
(150MHz, DMSO-d6): 182.5 (C-4), 164.0 (C-2), 158.1 (C-7),
153.1 (C-5), 152.9 (C-9), 148.6 (C-3ó¸€ , 5ó¸€ ), 140.3 (C-4ó¸€ ), 131.9 (C-
6), 120.9 (C-1ó¸€ ), 104.8 (C-2ó¸€ , 6ó¸€ ), 104.4 (C-10), 103.5 (C-3), 94.9
(C-8), 60.3 (6-OMe), 56.8 (3ó¸€ , 5ó¸€ -OMe).
Compound 7: C18H18O8; ESI/LTQ-Orbitrap-MS m/z:
375.11 [M+H]+; 1H-NMR (600MHz, DMSO-d6): 1H-NMR
(600MHz, DMSO-d6): 12.91 (5-OH), 7.28 (2H, s, H-2ó¸€ , 6ó¸€ ),
6.99 (1H, s, H-3), 6.63 (1H, s, H-8), 3.87 (6H, s, 6, 4ó¸€ -OMe),
3.73 (6H, s, 3ó¸€ , 5ó¸€ -OMe); 13C-NMR (150MHz, DMSO-d6):
182.5 (C-4), 163.4 (C-2), 158.7 (C-7), 153.7 (C-2ó¸€ , 5ó¸€ ), 153.1 (C-
5), 152.5 (C-9), 141.1 (C-4ó¸€ ), 132.1 (C-6), 126.5 (C-1ó¸€ ), 104.9 (C-
2ó¸€ ), 104.5 (C-6ó¸€ ), 104.2 (C-10), 103.8 (C-3), 95.2 (C-8), 60.6 (6-
OMe), 60.3 (4ó¸€ -OMe), 56.7 (3ó¸€ , 5ó¸€ -OMe).
Compound 8: C22H22O13; FAB-MS m/z: 495 [M+H]+;
1H-NMR (600MHz, DMSO-d6): 13.01 (5-OH), 7.69 (1H, d, J
= 2.4Hz,H-2ó¸€ ), 7.58 (1H, dd, J = 2.4, 8.4Hz,H-6ó¸€ ), 6.86 (1H, d,
J = 8.4Hz, H-5ó¸€ ), 6.48 (1H, s, H-8), 5.26 (1H, d, J = 7.8Hz, Glc
H-1), 3.86 (3H, s, 6-OMe); 13C-NMR (150MHz, DMSO-d6):
179.4 (C-4), 158.8 (C-9), 158.5 (C-2), 153.5 (C-5), 153.3 (C-7),
149.5 (C-4ó¸€ ), 145.6 (C-5ó¸€ ), 135.0 (C-3), 132.3 (C-6), 122.9 (C-
1ó¸€ ), 122.8 (C-6ó¸€ ), 117.2 (C-2ó¸€ ), 115.7 (C-3ó¸€ ), 105.8 (C-10), 103.9
(Glc C-1), 94.6 (C-8), 78.1 (Glc C-5), 77.8 (Glc C-3), 75.4 (Glc
C-2), 70.9 (Glc C-4), 62.2 (Glc C-6), 60.6 (6-OMe).
Compound 9: C22H20O12; FAB-MS m/z: 465 [M+H]+;
1H-NMR (600MHz, DMSO-d6): 13.01 (5-OH), 7.55 (1H, d, J
= 1.2Hz, H-2ó¸€ ), 7.54 (1H, dd, J = 1.2, 9.0Hz, H-6ó¸€ ), 6.84 (1H, d,
J = 9.0Hz, H-5ó¸€ ), 6.36 (1H, s, H-8), 6.15 (1H, s, H-6), 5.41 (1H,
d, J = 7.8Hz, Glc H-1); 13C-NMR (150MHz, DMSO-d6): 177.4
(C-4), 161.1 (C-7), 157.2 (C-5), 156.7 (C-2), 156.3 (C-9), 148.6
(C-4ó¸€ ), 144.9 (C-3ó¸€ ), 133.5 (C-3), 121.9 (C-6ó¸€ ), 121.4 (C-1ó¸€ ), 116.3
(C-5ó¸€ ), 115.4 (C-2ó¸€ ), 103.7 (C-10), 101.2 (Glc C-1), 99.2 (C-6),
94.6 (C-8), 77.6 (Glc C-5), 76.5 (Glc C-3), 74.2 (Glc C-2), 70.1
(Glc C-4), 61.0 (Glc C-6).
Compound 10: C27H30O17; ESI/LTQ-Orbitrap-MS m/z:
649.45 [M+Na]+; 1H-NMR (600MHz, DMSO-ğ‘‘6):
1H-NMR
BioMed Research International 5
O O
MeO
RO
R
Scopoletin (1) H
Scopolin (2) Glucose
O
OH O
Genkwanin (3) Me H H H H H
Hispidulin (4) H OMe H H H H
Jaceosidin (5) H OMe H H H OMe
6-Methoxytricin (6) H OMe H H OMe OMe
Arteanoflavone (7) H OMe H Me OMe OMe
Patuletin-3-O-glucoside (8) H OMe O-Glucose H OH H
Isoquercetin (9) H H O-Glucose H OH H
Quercetin-3-gentiobioside (10) H H O-Glucose-glucose H OH H
Rutin (11) H H O-Glucose-rhamnose H OH H
Caffeoyl = 
O
OH
OH
3-O-Caffeoylquinic acid (12) Caffeoyl H H H H
1,3-Di-O-caffeoylquinic acid (13) Caffeoyl H H Caffeoyl H
3,4-Di-O-caffeoylquinic acid (14) Caffeoyl Caffeoyl H H H
3,5-Di-O-caffeoylquinic acid (15) Caffeoyl H Caffeoyl H H
3,5-Di-O-caffeoylquinic acid methyl ester (16) Caffeoyl H Caffeoyl H Me
OH
O
R
O
HO
OH
OH
HO
R
Iwayoside A (17) î‹¤-OH
Suavioside A (18) î‹£-OH
Sugeroside (19) =O
OMe
OHO
O
OH
HO
HO
OH
O
ï¼’5
ï¼’1O
ï¼’2
Oï¼’4
ï¼’6
ï¼’1 ï¼’2 ï¼’3 ï¼’4 ï¼’5 ï¼’6
ï¼’4O
ï¼’1O Oï¼’3
Oï¼’2
COOï¼’5
ï¼’1 ï¼’2 ï¼’3 ï¼’4 ï¼’5
2,4-Dihydroxy-6-methoxyacetophenone 4-O-î‹¤-d-glucopyranoside (20)
Figure 1: Structures of the compounds 1â€“20.
6 BioMed Research International
(600MHz, DMSO-ğ‘‘6): 13.04 (5-OH), 7.64 (1H, d, J = 2.4Hz,
H-2ó¸€ ), 7.51 (1H, dd, J = 2.4, 8.4Hz, H-6ó¸€ ), 6.82 (1H, d, J =
8.4Hz, H-5ó¸€ ), 6.36 (1H, s, H-8), 6.14 (1H, s, H-6), 5.31 (1H, d, J
= 7.8Hz, Glc H-1), 5.29 (1H, d, J = 7.8Hz, Glc H-1ó¸€ ); 13C-NMR
(150MHz, DMSO-ğ‘‘6): 177.4 (C-4), 165.3 (C-5), 161.2 (C-7),
156.7 (C-2), 155.8 (C-9), 148.6 (C-3ó¸€ ), 144.9 (C-4ó¸€ ), 133.3 (C-
3), 122.3 (C-6ó¸€ ), 121.5 (C-1ó¸€ ), 115.9 (C-5ó¸€ ), 115.4 (C-2ó¸€ ), 108.9
(C-10), 103.8 (Glc C-1), 99.2 (Glc C-1ó¸€ ), 98.8 (C-6), 94.0 (C-8),
79.3 (Glc C-5), 77.6 (Glc C-3), 77.5 (Glc C-5ó¸€ ), 77.1 (Glc C-3ó¸€ ),
76.4 (Glc C-2, 2ó¸€ ), 74.2 (Glc C-4), 70.3 (Glc C-4ó¸€ ), 64.3 (Glc
C-6), 60.9 (Glc C-6ó¸€ ).
Compound 11: C27H30O16; FAB-MS m/z: 611 [M+H]+;
1H-NMR (600MHz, DMSO-ğ‘‘6): 13.01 (5-OH), 7.53 (1H, d, J
= 2.4Hz, H-2ó¸€ ), 7.51 (1H, dd, J = 2.4, 8.4Hz, H-6ó¸€ ), 6.83 (1H, d,
J = 8.4Hz, H-5ó¸€ ), 6.35 (1H, s, H-8), 6.15 (1H, s, H-6), 5.29 (1H,
d, J = 4.2Hz, Glc H-1), 4.37 (1H, s, Rham H-1), 0.96 (3H, d, J
= 6.5Hz, Rham H-6); 13C-NMR (150MHz, DMSO-ğ‘‘6): 177.1
(C-4), 164.9 (C-7), 160.8 (C-5), 156.5 (C-2, 9), 148.2 (C-4ó¸€ ),
144.5 (C-3ó¸€ ), 133.2 (C-3), 121.6 (C-6ó¸€ ), 121.1 (C-1ó¸€ ), 116.0 (C-
5ó¸€ ), 115.1 (C-2ó¸€ ), 103.5 (C-10), 101.2 (Glc C-1), 100.6 (Rham C-
1), 98.9 (C-6), 93.8 (C-8), 76.2 (Glc C-3), 75.7 (Glc C-5), 73.9
(Glc C-2), 71.7 (Rham C-4), 70.4 (Rham C-2), 70.2 (Rham
C-3), 69.8 (Glc C-4), 68.2 (Rham C-5), 67.0 (Glc C-6), 17.6
(Rham C-6).
Compound 12: C16H18O9; ESI/LTQ-Orbitrap-MS m/z:
376.26 [M+Na]+; 1H-NMR (600MHz, CD3OD): 7.57 (1H, d,
J = 15.6Hz, H-7ó¸€ ), 6.97 (1H, d, J = 1.8Hz, H-2ó¸€ ), 6.86 (1H,
dd, J = 1.8, 7.8Hz, H-6ó¸€ ), 6.71 (1H, d, J = 7.8Hz, H-5ó¸€ ), 6.25
(1H, d, J = 15.6Hz, H-8ó¸€ ), 5.06 (1H, m, H-3), 4.16 (1H, m, H-
5), 3.82 (1H, m, H-4), 2.03â€“1.79 (4H, m, H-2, 6); 13C-NMR
(150MHz, CD3OD): 178.2 (1-COOH), 170.5 (C-9
ó¸€ ), 151.4 (C-
4ó¸€ ), 149.3 (C-7ó¸€ ), 148.9 (C-3ó¸€ ), 129.6 (C-1ó¸€ ), 125.0 (C-6ó¸€ ), 118.4
(C-5ó¸€ ), 117.1 (C-2ó¸€ ), 116.8 (C-8ó¸€ ), 76.5 (C-1), 74.0 (C-3), 72.6
(C-4), 71.2 (C-5), 39.6 (C-2), 39.2 (C-6).
Compound 13: C25H24O12; FAB-MS m/z: 517 [M+H]+;
1H-NMR (600MHz, CD3OD): 7.63 (1H, d, J = 16.2Hz,H-7ó¸€ ó¸€ ),
7.56 (1H, d, J = 16.2Hz, H-7ó¸€ ), 7.08 (1H, d, J = 4.2Hz, H-1ó¸€ ó¸€ ),
7.06 (1H, d, J = 4.2Hz, H-1ó¸€ ), 7.03 (1H, d, J = 1.8Hz, H-2ó¸€ ), 7.00
(1H, d, J = 1.8Hz, H-2ó¸€ ó¸€ ), 6.97 (1H, dd, J = 1.8, 6.6Hz, H-6ó¸€ ó¸€ ),
6.96 (1H, d, J = 6.6Hz, H-5ó¸€ ó¸€ ), 6.80 (1H, dd, J = 1.8, 6.6Hz,
H-6ó¸€ ), 6.78 (1H, d, J = 6.6Hz, H-5ó¸€ ), 6.34 (1H, d, 2 = 16.2Hz,
H-8ó¸€ ó¸€ ), 6.26 (1H, d, J = 16.2Hz, H-8ó¸€ ), 5.44 (1H, m, H-3), 4.31
(1H, d, J = 4.2Hz, H-5), 3.99 (1H, dd, J = 3.7, 7.2Hz, H-4),
2.33 (2H, m, H-6), 2.15 (2H, m, H-2); 13C-NMR (150MHz,
CD3OD): 177.5 (1-COOH), 169.0 (C-9
ó¸€ ó¸€ ), 168.9 (C-9ó¸€ ), 149.6
(C-4ó¸€ ó¸€ ), 149.5 (C-4ó¸€ ), 147.8 (C-3ó¸€ ó¸€ ), 147.4 (C-7ó¸€ , 7ó¸€ ó¸€ ), 146.2 (C-
3ó¸€ ), 128.0 (C-1ó¸€ ó¸€ ), 127.9 (C-1ó¸€ ), 123.2 (C-6ó¸€ ó¸€ ), 123.1 (C-6ó¸€ ), 116.6
(C-5ó¸€ , 5ó¸€ ó¸€ ), 115.7 (C-8ó¸€ ó¸€ ), 115.4 (C-8ó¸€ ), 115.3 (C-2ó¸€ ó¸€ ), 115.2 (C-2ó¸€ ),
81.0 (C-1), 74.8 (C-4), 72.7 (C-3), 72.2 (C-5), 37.7 (C-6), 36.4
(C-2).
Compound 14: C25H24O12; Q-TOF-MS m/z: 515.1185
[Mâˆ’H]âˆ’; 1H-NMR (600MHz, CD3OD): 7.60 (1H, d, J =
15.6Hz, H-7ó¸€ ), 7.52 (1H, d, J = 15.6Hz, H-7ó¸€ ó¸€ ), 7.03 (1H, d, J
= 1.8Hz, H-2ó¸€ ), 7.00 (1H, d, J = 1.8Hz, H-2ó¸€ ó¸€ ), 6.92 (2H, m, H-
6ó¸€ , 6ó¸€ ó¸€ ), 6.76 (1H, d, J = 7.8Hz, H-5ó¸€ ), 6.74 (1H, d, J = 7.8Hz,
H-5ó¸€ ó¸€ ), 6.29 (1H, d, J = 15.6Hz, H-8ó¸€ ), 6.20 (1H, d, J = 15.6Hz,
H-8ó¸€ ó¸€ ), 5.65 (1H, m, H-3), 5.12 (1H, dd, J = 3.0, 9.0Hz, H-4),
4.36 (1H, d, J = 3.0Hz, H-5), 2.35 (2H, m, H-6), 2.13 (2H, m,
H-2); 13C-NMR (150MHz, CD3OD): 177.2 (1-COOH), 170.6
(C-9ó¸€ ), 170.3 (C-9ó¸€ ó¸€ ), 151.5 (C-4ó¸€ , 4ó¸€ ó¸€ ), 149.7 (C-7ó¸€ ), 149.5 (C-
7ó¸€ ó¸€ ), 148.6 (C-3ó¸€ , 3ó¸€ ó¸€ ), 129.6 (C-1ó¸€ ), 129.5 (C-1ó¸€ ó¸€ ), 125.1 (C-6ó¸€ ,
6ó¸€ ó¸€ ), 118.4 (C-5ó¸€ , 5ó¸€ ó¸€ ), 117.1 (C-2ó¸€ , 2ó¸€ ó¸€ ), 116.6 (C-8ó¸€ , 8ó¸€ ó¸€ ), 78.0 (C-
1), 77.9 (C-4), 71.5 (C-5), 71.0 (C-3), 41.4 (C-2), 40.3 (C-6).
Compound 15: C25H24O12; Q-TOF-MS m/z: 515.1185
[Mâˆ’H]âˆ’; 1H-NMR (600MHz, CD3OD): 7.62 (1H, d, J =
16.2Hz, H-7ó¸€ ), 7.58 (1H, d, J = 16.2Hz, H-7ó¸€ ó¸€ ), 7.07 (2H, t, J
= 1.8, 4.2Hz, H-2ó¸€ , 2ó¸€ ó¸€ ), 6.96 (2H, m, H-6ó¸€ , 6ó¸€ ó¸€ ), 6.75 (1H, d,
J = 7.8Hz, H-5ó¸€ ), 6.72 (1H, d, J = 7.8Hz, H-5ó¸€ ó¸€ ), 6.36 (1H, d,
J = 16.2Hz, H-8ó¸€ ), 6.28 (1H, d, J = 16.2Hz, H-8ó¸€ ó¸€ ), 5.41 (1H,
m, H-3), 5.39 (1H, m, H-5), 3.98 (1H, dd, J = 3.6, 7.8Hz, H-4),
2.35 (2H, m, H-6), 2.20 (2H, m, H-2); 13C-NMR (150MHz,
CD3OD): 179.4 (1-COOH), 170.9 (C-9
ó¸€ ), 170.4 (C-9ó¸€ ó¸€ ), 151.5
(C-4ó¸€ ), 151.4 (C-4ó¸€ ó¸€ ), 149.2 (C-7ó¸€ , 7ó¸€ ó¸€ ), 149.0 (C-3ó¸€ ), 148.6 (C-
3ó¸€ ó¸€ ), 129.8 (C-1ó¸€ ), 129.7 (C-1ó¸€ ó¸€ ), 125.0 (C-6ó¸€ ), 124.9 (C-6ó¸€ ó¸€ ), 118.4
(C-5ó¸€ , 5ó¸€ ó¸€ ), 117.5 (C-8ó¸€ ), 117.2 (C-8ó¸€ ó¸€ ), 117.1 (C-2ó¸€ ), 117.0 (C-2ó¸€ ó¸€ ),
76.7 (C-1), 74.5 (C-5), 74.0 (C-3), 72.6 (C-4), 39.7 (C-2), 38.0
(C-6).
Compound 16: C26H26O12; Q-TOF-MS m/z: 529.1349
[Mâˆ’H]âˆ’; 1H-NMR (600MHz, CD3OD): 7.63 (1H, d, J =
16.2Hz, H-7ó¸€ ), 7.56 (1H, d, J = 16.2Hz, H-7ó¸€ ó¸€ ), 7.07 (1H, d,
J = 2.4Hz, H-2ó¸€ ), 7.06 (1H, d, J = 2.4Hz, H-2ó¸€ ó¸€ ), 6.97 (2H,
m, H-6ó¸€ , 6ó¸€ ó¸€ ), 6.80 (1H, d, J = 8.4Hz, H-5ó¸€ ), 6.78 (1H, d, J
= 8.4Hz, H-5ó¸€ ó¸€ ), 6.35 (1H, d, J = 16.2Hz, H-8ó¸€ ), 6.23 (1H,
d, J = 16.2Hz, H-8ó¸€ ó¸€ ), 5.41 (1H, m, H-3), 5.32 (1H, m, H-5),
3.98 (1H, dd, J = 3.0, 6.6Hz, H-4), 3.69 (3H, s, 1-COOMe),
2.35 (2H, m, H-6), 2.20 (2H, m, H-2); 13C-NMR (150MHz,
CD3OD): 177.5 (1-COOMe), 170.6 (C-9
ó¸€ ), 169.8 (C-9ó¸€ ó¸€ ), 151.6
(C-4ó¸€ ), 151.4 (C-4ó¸€ ó¸€ ), 149.3 (C-7ó¸€ ), 149.0 (C-7ó¸€ ó¸€ ), 148.7 (C-3ó¸€ ),
148.6 (C-3ó¸€ ó¸€ ), 129.7 (C-1ó¸€ ), 129.4 (C-1ó¸€ ó¸€ ), 124.9 (C-6ó¸€ ), 124.8 (C-
6ó¸€ ó¸€ ), 118.4 (C-5ó¸€ ), 118.3 (C-5ó¸€ ó¸€ ), 117.2 (C-8ó¸€ , 8ó¸€ ), 117.0 (C-2ó¸€ , 2ó¸€ )
76.5 (C-1), 74.0 (C-5), 73.8 (C-3), 72.6 (C-4), 54.9 (1-COOMe),
38.5 (C-2), 37.5 (C-6).
Compound 17: C26H44O8; ESI/LTQ-Orbitrap-MS m/z:
507.29 [M+Na]+; 1H-NMR (600MHz, Pyridine-ğ‘‘6): 5.06
(1H, d, J = 8.4Hz, Glc H-1), 4.52 (1H, d, J = 10.6Hz, H-17a),
4.12 (1H, t, H-3), 3.95 (1H, d, J = 10.6Hz, H-17b), 2.43 (1H, s,
H-14a), 2.02 (1H, m, H-13), 1.94 (1H, m, H-2a), 1.88 (1H, m,
H-1a), 1.82 (1H, m, H-15a), 1.78 (1H, m, H-14b), 1.66 (1H, m,
H-7a), 1.65 (2H, m, H-11), 1.64 (1H, m, H-6a), 1.57 (1H, m, H-
5), 1.47 (1H, m, H-7b), 1.42 (1H, m, H-6b), 1.35 (1H, m, 15b),
1.34 (1H,m, H-2b), 1.21 (3H, s, 20), 1.02 (3H, s, 19), 0.99 (3H, s,
18), 0.98 (1H, m, H-9), 0.89 (1H, m, 1b); 13C-NMR (150MHz,
pyridine-ğ‘‘6): 105.7 (Glc C-1), 82.5 (C-16), 80.1 (C-3), 78.4 (Glc
C-5), 78.3 (Glc C-3), 75.7 (Glc C-2), 75.5 (C-17), 72.1 (Glc C-
4), 63.2 (Glc C-6), 58.6 (C-9), 56.9 (C-5), 54.0 (C-15), 47.2 (C-
13), 46.0 (C-8), 43.6 (C-7), 40.6 (C-10), 40.4 (C-4), 40.3 (C-1),
38.5 (C-14), 29.3 (C-19), 28.4 (C-2), 27.7 (C-12), 21.7 (C-6), 19.9
(C-11), 18.8 (C-20), 16.6 (C-18).
Compound 18: C26H44O8; ESI/LTQ-Orbitrap-MS m/z:
507.29 [M+Na]+; 1H-NMR(600MHz, Pyridine-ğ‘‘6): 5.05 (1H,
d, J = 7.8Hz, Glc H-1), 4.49 (1H, d, J = 10.6Hz, H-17a), 4.12
(1H, t, H-3), 3.92 (1H, d, J = 10.6Hz, H-17b), 2.45 (1H, s, H-
14a), 2.02 (1H, m, H-13), 1.94 (1H, m, H-2a), 1.88 (1H, m, H-
1a), 1.82 (1H, m, H-15a), 1.78 (1H, m, H-14b), 1.66 (1H, m, H-
7a), 1.65 (2H, m, H-11), 1.64 (1H, m, H-6a), 1.57 (1H, m, H-5),
1.47 (1H, m, H-7b), 1.42 (1H, m, H-6b), 1.35 (1H, m, 15b), 1.34
(1H, m, H-2b), 1.18 (3H, s, 20), 1.02 (3H, s, 19), 0.98 (1H, m,
H-9), 0.89 (1H, m, 1b), 0.88 (3H, s, 18); 13C-NMR (150MHz,
BioMed Research International 7
Table 1: IC50 of the extraction and fractions from A. iwayomogi on
aldose reductase (AR) and advanced glycation endproducts (AGEs)
formation.
Sample IC50
ğ‘ (ğœ‡g/ml)
AR AGEs formation
50% EtOH ext. 2.71 Â± 0.72âˆ—âˆ— 40.99 Â± 0.50âˆ—
CHCl3 fr. 15.36 Â± 3.64
âˆ—âˆ— 7.29 Â± 0.05âˆ—
30% MeOH fr. 1.16 Â± 0.10âˆ— 40.81 Â± 0.05âˆ—
60% MeOH fr. 1.42 Â± 0.17âˆ— 93.76 Â± 0.06âˆ—
100% MeOH fr. 0.79 Â± 0.15âˆ— 38.40 Â± 0.51âˆ—
Water fr. 19.67 Â± 0.81âˆ—âˆ— 402.45 Â± 4.28âˆ—âˆ—
TMGb 1.22 Â± 0.03âˆ— â€”
AGc â€” 45.85 Â± 7.17âˆ—âˆ—
ğ‘IC50 calculated from the least-squares regression line of the logarithmic
concentrations plotted against the residual activity.
ğ‘TMG was used as a positive control.
ğ‘AG was used as a positive control.
âˆ—Significant difference from control; âˆ—ğ‘ < 0.05, âˆ—âˆ—ğ‘ < 0.01.
Pyridine-ğ‘‘6): 107.4 (Glc C-1), 81.5 (C-16), 79.4 (Glc C-5), 79.3
(Glc C-3), 76.4 (Glc C-2), 76.2 (C-17), 75.8 (C-3), 72.3 (Glc
C-4), 63.5 (Glc C-6), 57.5 (C-9), 54.0 (C-15), 49.6 (C-5), 47.2
(C-13), 45.5 (C-8), 43.1 (C-7), 40.2 (C-10), 38.7 (C-4), 38.2 (C-
14), 34.5 (C-1), 30.1 (C-18), 27.6 (C-2), 27.1 (C-12), 23.1 (C-19),
21.1 (C-6), 19.2 (C-20), 18.6 (C-11).
Compound 19: C26H42O8; FAB-MS m/z: 481 [Mâˆ’H]âˆ’;
1H-NMR (600MHz, DMSO-ğ‘‘6): 4.16 (1H, d, J = 7.8Hz, Glc
H-1), 4.03 (1H, d, J = 10.8Hz, H-17a), 3.38 (1H, d, J = 10.8Hz,
H-17a), 2.43 (1H, m, H-2a), 1.99 (1H, m, H-13), 1.92 (1H, m,
H-1), 1.82 (1H, m, H-2b), 1.77 (2H, m, H-14), 1.58 (1H, m, H-
5), 1. 57 (1H, m, H-15a), 1.56 (2H, m, H-11), 1.51 (2H, m, H-12),
1.45 (2H, m, H-7), 1.40 (2H, m, H-6), 1.35 (1H, m, H-15b), 1.07
(1H, m, H-9), 0.99 (6H, s, H-18, 20), 0.93 (3H, s, H-19); 13C-
NMR (150MHz, DMSO-ğ‘‘6): 218.7 (C-3), 105.8 (Glc C-1), 81.2
(C-16), 81.0 (Glc C-5), 77.6 (Glc C-3), 75.3 (Glc C-2), 75.1 (C-
17), 71.5 (Glc C-4), 62.5 (Glc C-6), 56.3 (C-9), 54.8 (C-5), 53.2
(C-15), 48.0 (C-4), 46.3 (C-13), 45.3 (C-8), 42.1 (C-7), 40.1 (C-
1), 39.5 (C-10), 37.8 (C-14), 35.1 (C-2), 28.4 (C-18), 27.3 (C-12),
22.8 (C-6), 22.2 (C-19), 19.9 (C-11), 19.0 (C-20).
Compound 20: C15H20O9; FAB-MS m/z: 335 [M+H]+;
1H-NMR (600MHz, CD3OD): 6.27 (1H, d, J = 2.4Hz, H-
5), 6.19 (1H, d, J = 2.4Hz, H-3), 5.04 (1H, d, J = 7.8Hz, Glc
H-1), 3.89 (3H, s, 6-OMe), 2.59 (3H, s, COCH3);
13C-NMR
(150MHz, CD3OD): 206.2 (COCH3), 166.7 (C-2), 165.2 (C-
4), 164.8 (C-6), 107.9 (C-1), 100.8 (Glc C-1), 97.4 (C-3), 93.2
(C-5), 77.9 (Glc C-3), 77.2 (Glc C-5), 74.3 (Glc C-2), 70.9 (Glc
C-4), 62.0 (Glc C-6), 56.7 (6-OMe), 33.3 (COCH3).
3.2. AR Inhibitory Activities of the Extracts, Fractions, and
Compounds 1â€“20 from A. iwayomogi. Our study investi-
gated the inhibitory effects of A. iwayomogi on AR and
AGEs formation, which demonstrates the potential of these
compounds to prevent diabetes complications. The extracts
and fractions of the aerial parts of the A. iwayomogi were
tested for AR inhibition. The results are summarized in
Table 1. The extracts, 30%, 60%, and 100% MeOH fractions
from A. iwayomogi showed significant inhibition of AR
Table 2: IC50 of compounds 1â€“20 isolated from A. iwayomogi on
aldose reductase (AR) and advanced glycation endproducts (AGEs)
formation.
Compound IC50
ğ‘ (ğœ‡M)
AR AGEs formation
1 90.39 Â± 1.91âˆ—âˆ— 20.71 Â± 1.38âˆ—âˆ—
2 131.37 Â± 0.12âˆ— 82.43 Â± 1.52âˆ—âˆ—
3 >200 311.89 Â± 11.26âˆ—âˆ—
4 2.93 Â± 0.11âˆ—âˆ— 185.56 Â± 0.20âˆ—âˆ—
5 110.65 Â± 9.89âˆ—âˆ— 169.61 Â± 16.41âˆ—âˆ—
6 30.29 Â± 3.95âˆ— 134.88 Â± 0.84âˆ—âˆ—
7 102.53 Â± 7.81âˆ—âˆ— 207.70 Â± 13.32âˆ—âˆ—
8 3.19 Â± 0.10âˆ—âˆ— 197.38 Â± 11.03âˆ—âˆ—
9 3.32 Â± 0.21âˆ—âˆ— 67.42 Â± 9.95âˆ—âˆ—
10 10.60 Â± 0.38âˆ—âˆ— 109.46 Â± 1.41âˆ—âˆ—
11 12.53 Â± 0.20âˆ—âˆ— 129.15 Â± 4.01âˆ—âˆ—
12 4.54 Â± 0.16âˆ—âˆ— 176.16 Â± 5.77âˆ—âˆ—
13 0.22 Â± 0.01âˆ—âˆ— 24.85 Â± 1.86âˆ—âˆ—
14 1.90 Â± 0.01âˆ—âˆ— 124.28 Â± 4.25âˆ—âˆ—
15 1.25 Â± 0.01âˆ—âˆ— 31.78 Â± 0.56âˆ—âˆ—
16 1.48 Â± 0.04âˆ—âˆ— 44.45 Â± 4.86âˆ—âˆ—
17 >200 NDd
18 >200 NDd
19 >200 NDd
20 >200 1048.99 Â± 0.11âˆ—
TMGb 6.58 Â± 0.19âˆ— â€”
AGc â€” 414.77 Â± 5.96âˆ—
ğ‘IC50 calculated from the least-squares regression line of the logarithmic
concentrations plotted against the residual activity.
ğ‘TMG was used as a positive control.
ğ‘AG was used as a positive control.
ğ‘‘ND was not detected.
âˆ—Significant difference from control; âˆ—ğ‘ < 0.05, âˆ—âˆ—ğ‘ < 0.01.
(IC50 value with 2.71 Â± 0.72, 1.16 Â± 0.10, 1.42 Â± 0.17, and
0.79 Â± 0.15ğœ‡g/mL, resp.). In addition, compounds 1â€“20
were tested for their ability to inhibit AR. As can be seen
in Table 2, genkwanin (3), the three diterpene glycosides
(17â€“19), and 2,4-dihydroxy 6-methoxyacetophenone 4-O-ğ›½-
d-glucopyranoside (20) demonstrated no AR inhibition; all
had IC50 values > 200 ğœ‡M. On the other hand, hispidulin
(4), patuletin-3-O-glucoside (8), isoquercetin (9), and five
caffeoylquinic acids (12, 13, 14, 15, and 16) were stronger
inhibitors than TMG (IC50 value with 6.58 Â± 0.19 ğœ‡M), which
was used as the positive control, as a compound known to
inhibit AR.The IC50 values of compounds4,8,9, 12, 13, 14, 15,
and 16were 2.93Â± 0.11, 3.19Â± 0.10, 3.32Â± 0.21, 4.54Â± 0.16, 0.22
Â± 0.01, 1.90Â± 0.01, 1.25Â± 0.01, and 1.48Â± 0.04ğœ‡M, respectively.
3.3. Inhibitory Activities of the Extracts, Fractions, and Com-
pounds 1â€“20 from A. iwayomogi on AGEs Formation. The
extracts and fractions from A. iwayomogi were investigated
for inhibition of AGEs formation. The results are shown in
Table 1. The extracts, CHCl3, 30% MeOH, and 100% MeOH
fractions all showed greater inhibition than AG (IC50 value
with 45.85 Â± 7.17 ğœ‡g/mL), the positive control.The IC50 values
8 BioMed Research International
Table 3: Contents of compounds 1, 2, 8, 10, 11, 12, 14, and 15 in A. iwayomogi by region in Korea.
Sample Contents (mg/g)
1 2 8 10 11 12 14 15
Seoul 1.38 Â± 0.01 1.16 Â± 0.02 4.80 Â± 0.03 0.25 Â± 0.20 0.69 Â± 0.42 16.79 Â± 0.19 7.43 Â± 0.18 55.86 Â± 0.79
Gyeonggi-do 0.98 Â± 0.01 1.49 Â± 0.01 1.64 Â± 0.03 0.23 Â± 0.07 0.23 Â± 0.01 4.18 Â± 0.05 3.40 Â± 0.01 30.83 Â± 0.06
Jechon, Chungcheongbuk-do 0.57 Â± 0.10 0.43 Â± 0.01 1.25 Â± 0.06 0.22 Â± 0.02 0.27 Â± 0.01 5.62 Â± 0.05 2.90 Â± 0.02 32.44 Â± 0.28
Imsil, Jeollabuk-do 0.26 Â± 0.01 0.30 Â± 0.01 0.96 Â± 0.04 0.14 Â± 0.02 0.38 Â± 0.04 2.56 Â± 0.22 2.23 Â± 0.03 17.82 Â± 0.07
Jinan, Jeollabuk-do 0.96 Â± 0.04 0.70 Â± 0.01 1.85 Â± 0.01 0.36 Â± 0.02 0.25 Â± 0.04 5.46 Â± 0.17 4.11 Â± 0.03 27.51 Â± 0.43
Hwasun, Jeonllanam-do 0.19 Â± 0.01 0.62 Â± 0.01 1.99 Â± 0.09 0.26 Â± 0.03 0.32 Â± 0.02 1.66 Â± 0.14 1.68 Â± 0.01 14.33 Â± 0.64
Gyeongju, Gyeongsangbuk-do 0.63 Â± 0.10 0.75 Â± 0.03 3.45 Â± 0.11 0.65 Â± 0.06 0.34 Â± 0.05 15.28 Â± 0.15 7.58 Â± 0.21 55.49 Â± 0.17
Uiseong, Gyeongsangbuk-do 0.50 Â± 0.01 0.61 Â± 0.03 1.27 Â± 0.02 0.07 Â± 0.05 0.43 Â± 0.26 5.45 Â± 0.23 1.63 Â± 0.01 25.44 Â± 0.05
Andong, Gyeongsangbuk-do 0.94 Â± 0.01 0.98 Â± 0.01 2.34 Â± 0.02 0.41 Â± 0.11 0.43 Â± 0.01 8.94 Â± 0.06 4.49 Â± 0.03 40.52 Â± 0.13
Yeongcheon, Gyeongsangbuk-do 0.29 Â± 0.01 0.43 Â± 0.01 1.21 Â± 0.03 0.10 Â± 0.03 0.51 Â± 0.02 4.32 Â± 0.15 1.94 Â± 0.01 21.99 Â± 0.27
Seongju, Gyeongsangbuk-do 0.73 Â± 0.03 0.29 Â± 0.01 1.18 Â± 0.01 0.20 Â± 0.02 0.27 Â± 0.01 3.07 Â± 0.09 2.36 Â± 0.03 21.92 Â± 0.07
Gunwi, Gyeongsangbuk-do 0.67 Â± 0.01 0.75 Â± 0.01 1.20 Â± 0.01 0.20 Â± 0.03 0.18 Â± 0.01 2.79 Â± 0.07 2.58 Â± 0.04 20.46 Â± 0.01
Sancheong, Gyeongsangnam-do 1.05 Â± 0.01 1.56 Â± 0.02 3.25 Â± 0.02 0.31 Â± 0.06 0.39 Â± 0.04 15.94 Â± 0.49 3.46 Â± 0.08 43.47 Â± 0.05
Jeju-do 0.12 Â± 0.03 1.59 Â± 0.02 4.03 Â± 0.10 0.35 Â± 0.10 1.11 Â± 0.07 17.45 Â± 0.19 5.34 Â± 0.03 48.22 Â± 0.95
Yangyang, Gangwon-do 0.74 Â± 0.02 1.67 Â± 0.02 3.95 Â± 0.45 0.59 Â± 0.12 0.53 Â± 0.02 33.61 Â± 0.48 8.18 Â± 0.10 68.87 Â± 0.19
Data are mean Â± SD (ğ‘› = 3) in mg/g dried sample.
(A
U
)
0.00
0.20
0.40
0.60
(Minutes)
1.
00
2.
00
3.
00
4.
00
5.
00
6.
00
7.
00
8.
00
9.
00
10
.0
0
11
.0
0
12
.0
0
13
.0
0
14
.0
0
15
.0
0
16
.0
0
17
.0
0
18
.0
0
19
.0
0
20
.0
0
2
12
10
11 8
1
15
14
(a)
(A
U
)
0.00
1.00
2.00
3.00
(Minutes)
1.
00
2.
00
3.
00
4.
00
5.
00
6.
00
7.
00
8.
00
9.
00
10
.0
0
11
.0
0
12
.0
0
13
.0
0
14
.0
0
15
.0
0
16
.0
0
17
.0
0
18
.0
0
19
.0
0
20
.0
0
14
18
12
2
10 11
15
(b)
Figure 2: Chromatograms of standards mixture (a) and A. iwayomogi ext. (b).
of extracts, CHCl3, 30% MeOH, and 100% MeOH fractions
were 40.99 Â± 0.50, 7.29 Â± 0.05, 40.81 Â± 0.05, and 38.40 Â±
0.51 ğœ‡g/mL, respectively. Compounds 1â€“20 isolated from A.
iwayomogiwere also tested for inhibition of AGEs formation,
as reported in Table 2. Similar to AR inhibitory activities,
diterpene glycosides (17â€“19) showed no inhibition of AGEs
formation and compound 20 showed only slight inhibition,
whereas the two coumarins (1 and 2), nine flavonoids (3â€“11),
and five caffeoylquinic acids (12â€“16) were all more inhibitory
than AG (IC50 value with 414.77 Â± 5.96 ğœ‡M). Among them,
compound 1, which exhibited minor inhibition on AR,
exhibited the best inhibition of AGEs formation with an IC50
value of 20.71 Â± 1.38 ğœ‡M.
3.4. Simultaneous Quantitative Analysis of Bioactive Com-
pounds in A. iwayomogi to Select Suitable Region in Korea.
Since A. iwayomogi is found mainly in Korea, we collected
15 samples of A. iwayomogi in different regions includ-
ing Seoul, Gyeongii-do, Chungcheongbuk-do, Jeollabuk-
do, Jeollanam-do, Gyeongsangbuk-do, Gyeongsangnam-do,
Gangwon-do, and Jeju-do. The following compounds were
analyzed by HPLC-PAD from these fifteen specimens:
scopoletin (1), scopolin (2), patulein-3-O-glucoside (8),
quercetin-3-gentiobioside (10), rutin (11), 3-O-caffeoylquinic
acid (12), 3,4-di-O-caffeoylquinic acid (14), and 3,5-di-O-
caffeoylquinic acid (15). They all showed significant inhibi-
tion of either AR or AGEs formation. Compounds 1, 2, 8, 10,
11, 12, 14, and 15 were detected in 14.4, 6.6, 13.3, 12.4, 12.7,
7.6, 16.9, and 15.9min, respectively (Figure 2). To optimize
analytical methods, the standard calibration curve, limit of
detection (LOD), and limit of quantification (LOQ) for com-
pounds 1, 2,8, 10, 11, 12, 14, and 15 aremeasured.The standard
calibration curves of compounds 1, 2, 8, 10, 11, 12, 14, and
15 were detected at linear range 0.1â€“1000ğœ‡g/mL. As a result,
the correlation coefficient (ğ‘Ÿ2) of all bioactive compounds is
above 0.999. The values of LOD of compounds 1, 2, 8, 10, 11,
12, 14, and 15 are shown to be 2.80, 0.50, 5.93, 5.08, 4.99, 3.82,
1.81, and 2.38 and the values of LOQ of bioactive compounds
are shown to be 8.49, 1.52, 17.98, 15.41, 15.12, 11.59, 5.48, and
7.21 ğœ‡g/mL, respectively. Using optimized analyticalmethods,
the amounts of bioactive compounds from A. iwayomogi in
the 15 sampleswere determined (Table 3). As a result, contents
of compounds 1 and 8 were the highest in Seoul (1.38 Â±
0.01, 4.80 Â± 0.03mg/g, resp.), compound 10 was the highest
in Gyeongju, Gyeongsangbuk-do (0.65 Â± 0.06mg/g), and
compound 11 was highest in Jeju-do (1.11 Â± 0.07mg/g). Fur-
thermore, compounds 2, 12, 14, and 15 were the most abun-
dant in Yangyang, Gangwon-do (1.67 Â± 0.02, 33.61 Â± 0.48,
BioMed Research International 9
0
20
40
60
80
100
120
140
Se
ou
l
G
ye
on
gg
i-d
o
Je
ch
on
Im
sil
Jin
an
H
w
as
un
G
ye
on
gj
u
U
ise
on
g
A
nd
on
g
Ye
on
gc
he
on
Se
on
gj
u
G
un
w
i
Sa
nc
he
on
g
Je
ju
-d
o
Ya
ng
ya
ng
Chungcheongbuk-do  Jeollabuk-do Jeonllanam-do Gyeongsangbuk-do Gyeongsangnam-do Gangwon-do
C
on
te
nt
s (
m
g/
g)
Region in Korea
Compound 15
Compound 14
Compound 12
Compound 11
Compound 10
Compound 8
Compound 2
Compound 1
(a)
0
20
40
60
80
100
120
140
June July August September October
C
on
te
nt
s (
m
g/
g)
Monthly in Yangyang, Gangwon-do
Compound 15
Compound 14
Compound 12
Compound 11
Compound 10
Compound 8
Compound 2
Compound 1
(b)
Figure 3: Total contents of compounds 1, 2, 8, 10, 11, 12, 14, and 15 in A. iwayomogi by region (a) and by month in Yangyang, Gangwon-do,
Korea (b).
8.18 Â± 0.10, and 68.87 Â± 0.19mg/g, resp.). Compound 2
exhibited good inhibition activity of AGEs formation while
compounds 12, 14, and 15 were significant inhibitors of both
AR and AGEs formation. Overall, the specimen with the
highest total contents of the most compounds was acquired
in Yangyang, Gangwon-do (Figure 3). We therefore col-
lected new specimens of A. iwayomogi in June, July, August,
September, and October in Yangyang, Gangwon-do, and
then analyzed the amounts of bioactive compounds in each
specimen using HPLC (Table 4). Amounts of compounds 1,
10, 12, and 14were taken in June (0.74Â± 0.02, 0.59Â± 0.12, 33.61
Â± 0.48, and 8.18 Â± 0.10mg/g, resp.), that of compound 15 was
taken in July (73.99Â± 0.35mg/g), those of compounds 2 and 8
were taken inAugust (3.67Â± 0.02 and 4.16Â± 0.04mg/g, resp.),
and that of compound 11 was taken in September (0.86 Â±
0.02mg/g).
4. Discussion
The worldwide prevalence of diabetes has become a massive
health burden significantly decreasing quality of life and
increasing morbidity, all at a huge economic cost. As diabetes
is recognized as a serious disease, diabetic complications are
also recognized as a serious disease. Accordingly, preventing
treatment for diabetic complications is as important as
diabetes and blocking the polyol pathway plays an important
role preventing diabetic complications. Therefore, AR and
AGEs formation inhibitors significantly affected diabetic
complications. Artemisia iwayomogi, locally called haninjin
or dowijigi, is a member of the Compositae family and a
perennial herbmainly found in Korea.A. iwayomogi has long
been used in Korea in foods such as tea, rice cake, and soup
and for the treatment of various diseases. However, previous
10 BioMed Research International
Table 4: Contents of compounds 1, 2, 8, 10, 11, 12, 14, and 15 from A. iwayomogi in Yangyang, Gangwon-do by month.
Sample Contents (mg/g)
1 2 8 10 11 12 14 15
June 0.74 Â± 0.02 1.67 Â± 0.02 3.95 Â± 0.45 0.59 Â± 0.12 0.53 Â± 0.02 33.61 Â± 0.48 8.18 Â± 0.10 68.87 Â± 0.19
July 0.08 Â± 0.01 1.81 Â± 0.01 3.19 Â± 0.08 0.31 Â± 0.04 0.47 Â± 0.01 19.74 Â± 0.08 7.73 Â± 0.02 73.99 Â± 0.35
August 0.28 Â± 0.01 3.67 Â± 0.02 4.16 Â± 0.04 0.30 Â± 0.04 0.67 Â± 0.09 15.15 Â± 0.01 4.97 Â± 0.08 49.99 Â± 0.99
September 0.20 Â± 0.01 2.24 Â± 0.01 3.71 Â± 0.01 0.21 Â± 0.02 0.86 Â± 0.02 7.81 Â± 0.13 2.88 Â± 0.01 40.97 Â± 0.50
October 0.19 Â±0.01 1.58 Â± 0.01 3.42 Â± 0.06 0.30 Â± 0.02 0.34 Â± 0.01 6.63 Â± 3.07 2.25 Â± 0.01 34.03 Â± 0.09
Data are mean Â± SD (ğ‘› = 3) in mg/g dried sample.
literatures did not have reported on inhibitory activities of A.
iwayomogi on AR and AGEs formation. For these reasons, we
aimed to assess Artemisia iwayomogi, which is native plant in
Korea used as usual food, and has potential as anti-diabetic
complications agent to inhibit AR and AGEs formation.
Our research led to the isolation of two coumarins
(1 and 2), nine flavonoids (3â€“11), five caffeoylquinic acids
(12â€“16), three diterpene glycosides (17â€“19), and one phenolic
compound (20). Among them, compounds 4, 6, 7, 10, 13, and
18 were first reported on the isolation from A. iwayomogi.
Compounds 1â€“20 have various bioactive properties such as
antioxidant, anti-inflammation, antiangiogenesis, and car-
diovascular activity [35â€“37].
After that, the extracts, fractions, and compounds 1â€“20
from A. iwayomogi were investigated for inhibition of AR.
The extracts, 30%, 60%, and 100% MeOH fractions from A.
iwayomogi showed significant inhibition of AR more than
TMG, positive control. Among compounds isolated from
A. iwayomogi, compounds 4, 8, 9, 12, 13, 14, 15, and 16
were stronger inhibitors than TMG. Out of these, compound
13 exhibited the strongest inhibition. Previous literature
reported that caffeic acid had no inhibitory activity on
AR but that caffeoyl derivatives are significant inhibitors of
AR [24, 38]. Existence of caffeoyl groups for substituents
such as quinicacid is important parameter for not only AR
inhibitory activity but also various biological activities [39].
Furthermore, other studies have demonstrated relationships
between the inhibitory activity and structure of flavonoids
[4]. They reported that monohydroxyflavones (such as com-
pound 3) are not inhibitors of AR, that flavonoid glucosides
(compounds 8 and 9) are more active than flavonoid diglu-
cosides (compounds 10 and 11), and that flavonoids with a
substituted hydroxyl group (compound 6) are more active
than those with substituted methoxyl groups (compound 7).
Inhibition of AR by flavonoids isolated from A. iwayomogi
in our study demonstrated similar results as previous studies.
We demonstrated the inhibitory activities of not only AR
but also AGEs formation. The CHCl3 fraction from A.
iwayomogi had no inhibitory activity on AR but showed the
best inhibition on AGEs formation. The two coumarins (1
and 2), nine flavonoids (3â€“11), and five caffeoylquinic acids
(12â€“16) exhibited also great inhibitory activities more than
AG, positive control. Among them, compound 1 showed
minor inhibition on AR and exhibited the best inhibition
of AGEs formation. Previous literature has reported that the
presence of a methoxyl group at C-6 instead of a hydroxyl
group and a hydroxyl group at C-7 in the coumarin structure
are important parameters in the inhibition of AGEs forma-
tion [40]. Therefore, compound 1 may be more active than
coumarins with other substituents.
SinceA. iwayomogi is foundmainly inKorea, we collected
15 samples of A. iwayomogi in different regions. The follow-
ing compounds were analyzed by HPLC-PAD from these
fifteen specimens: scopoletin (1), scopolin (2), patulein-3-O-
glucoside (8), quercetin-3-gentiobioside (10), rutin (11), 3-
O-caffeoylquinic acid (12), 3,4-di-O-caffeoylquinic acid (14),
and 3,5-di-O-caffeoylquinic acid (15). They all showed sig-
nificant inhibition of either AR or AGEs formation. Overall,
the most abundant bioactive compounds were harvested in
Yangyang, Gangwon-do, from June (Figure 3). We demon-
strated that A. iwayomogi, which was harvested in Yangyang,
Gangwon-do, from June, was the best used formedicinal food
such as diabetic complications.
5. Conclusion
In summary, our study reported the isolation of two
coumarins (1 and 2), nine flavonoids (3â€“11), five caf-
feoylquinic acids (12â€“16), three diterpene glycosides (17â€“19),
and one phenolic compound (20). Among them, hispidulin
(4), 6-methoxytricin (6), arteanoflavone (7), quercetin-3-
gentiobioside (10), 1,3-di-O-caffeoylquinic acid (13), and
suavioside A (18) were isolated for the first time from A.
iwayomogi. In addition, two coumarins, nine flavonoids,
and five caffeoylquinic acids isolated from A. iwayomogi
demonstrated biological activities against AR and AGEs
formation. Since extracts of A. iwayomogi contained enough
amounts of active compounds, A. iwayomogi extract can be
used for the successful crude herbal drug against AR and
AGEs formation. BecauseA. iwayomogi is native to Korea, we
analyzed the bioactive compounds by region.We determined
that it is best to harvestA. iwayomogi in Yangyang, Gangwon-
do, from June in order to get the highest content of active
compounds. Based on these, our research demonstrates
that A. iwayomogi containing active compounds is clearly a
potential candidate for a new natural alternative medicine or
health supplement and a preventive or therapeutic agent in
the treatment of diabetic complications.
Conflicts of Interest
All authors have no conflicts of interest to declare.
BioMed Research International 11
Acknowledgments
This research was supported by the Chung-Ang University
Graduate Research Scholarship in 2016 and Ministry of
Agriculture, Food and Rural Affairs, Republic of Korea.
References
[1] M. Saraswat, P. Muthenna, P. Suryanarayana, J. M. Petrash, and
G. B. Reddy, â€œDietary sources of aldose reductase inhibitors:
prospects for alleviating diabetic complications,â€ Asia Pacific
Journal of Clinical Nutrition, vol. 17, no. 4, pp. 558â€“565, 2008.
[2] J. G. Collins and C. N. Corder, â€œAldose reductase and sorbitol
dehydrogenase distribution in substructures of normal and
diabetic rat lens,â€ Investigative Ophthalmology & Visual Science,
vol. 16, no. 3, pp. 242â€“243, 1977.
[3] A. Kato, H. Yasuko, H. Goto, J. Hollinshead, R. J. Nash, and
I. Adachi, â€œInhibitory effect of rhetsinine isolated from Evodia
rutaecarpa on aldose reductase activity,â€ Phytomedicine, vol. 16,
no. 2-3, pp. 258â€“261, 2009.
[4] K. Kawanishi, H. Ueda, and M. Moriyasu, â€œAldose reductase
inhibitors from the nature,â€ Current Medicinal Chemistry, vol.
10, no. 15, pp. 1353â€“1374, 2003.
[5] N. Sasaki, R. Fukatsu, K. Tsuzuki et al., â€œAdvanced glycation end
products in Alzheimerâ€™s disease and other neurodegenerative
diseases,â€ American Journal of Pathology, vol. 153, no. 4, pp.
1149â€“1155, 1998.
[6] H. A. Jung, Y. S. Kim, and J. S. Choi, â€œQuantitative HPLC
analysis of two key flavonoids and inhibitory activities against
aldose reductase from different parts of the Korean thistle,
Cirsium maackii,â€ Food and Chemical Toxicology, vol. 47, no. 11,
pp. 2790â€“2797, 2009.
[7] S. S. Lim, S. H. Jung, J. Ji, K. H. Shin, and S. R. Keum, â€œSynthesis
of flavonoids and their effects on aldose reductase and sorbitol
accumulation in streptozotocin-induced diabetic rat tissues,â€
Journal of Pharmacy and Pharmacology, vol. 53, no. 5, pp. 653â€“
668, 2001.
[8] R. L. Kang, O. P. Zee, J. H. Kwak et al., â€œThe polysaccharide frac-
tions of Artemisia species,â€ Korean Journal of Pharmacognosy,
vol. 24, pp. 289â€“295, 1993.
[9] K. A. Koo, J. H. Kwak, K. R. Lee et al., â€œAntitumor and
immunomodulating activities of the polysaccharide fractions
from Artemisia selengensis and Artemisia iwayomogi,â€ Archives
of Pharmacal Research, vol. 17, no. 5, pp. 371â€“374, 1994.
[10] S.-H. Lee, Y. Ding, X. T. Yan, Y.-H. Kim, and H.-D. Jang,
â€œScopoletin and scopolin isolated from Artemisia iwayomogi
suppress differentiation of osteoclastic macrophage RAW 264.7
cells by scavenging reactive oxygen species,â€ Journal of Natural
Products, vol. 76, no. 4, pp. 615â€“620, 2013.
[11] S. S. Kim, C. K. Lee, S. S. Kang, H. A. Jung, and J. S.
Choi, â€œChlorogenic acid, an antioxidant principle from the
aerial parts of Artemisia iwayomogi that acts on 1,1-diphenyl-2-
picrylhydrazyl radical,â€ Archives of Pharmacal Research, vol. 20,
no. 2, pp. 148â€“154, 1997.
[12] Y.Ding, J. A. Kim, S. Y. Yang et al., â€œAntioxidative sesquiterpenes
from Artemisia iwayomogi,â€ Bulletin of the Korean Chemical
Society, vol. 32, no. 9, pp. 3493â€“3496, 2011.
[13] Y. Ding, C. Liang, S. Y. Yang et al., â€œPhenolic compounds from
Artemisia iwayomogi and their effects on osteoblastic MC3T3-
E1 cells,â€ Biological and Pharmaceutical Bulletin, vol. 33, no. 8,
pp. 1448â€“1453, 2010.
[14] X.-T. Yan, Y. Ding, W. Li et al., â€œTwo new phenolic compounds
from Artemisia iwayomogi,â€ Helvetica Chimica Acta, vol. 97, no.
2, pp. 283â€“289, 2014.
[15] T. S. Park, H. W. Kim, and H. K. Hwang, â€œNovel use of scopolin
and derivatives thereof,â€ Google patents, 2010.
[16] A. R. Kim, Y. N. Zou, T. H. Park et al., â€œActive components from
Artemisia iwayomogi displaying ONOOâˆ’ scavenging activity,â€
Phytotherapy Research, vol. 18, no. 1, pp. 1â€“7, 2004.
[17] J.-H. Ryul, H. Ahn, J. Y. Kim, and Y.-K. Kim, â€œInhibitory activity
of plant extracts on nitric oxide synthesis in LPS-activated
macrophages,â€Phytotherapy Research, vol. 17, no. 5, pp. 485â€“489,
2003.
[18] J. S. Hwang, H. J. Ji, K. A. Koo et al., â€œAIP1, a water-soluble
fraction from Artemisia iwayomogi, suppresses thymocyte
apoptosis in vitro and down-regulates the expression of fas
gene,â€ Biological and Pharmaceutical Bulletin, vol. 28, no. 5, pp.
921â€“924, 2005.
[19] H. J. Ji, H.K. Yeo,N.H. Lee et al., â€œA carbohydrate fraction,AIP1,
from Artemisia iwayomogi down-regulates Fas gene expression
and suppresses apoptotic death of the thymocytes induced
by 2,3,7,8-tectrachlorodibenzo-p-dioxin,â€ Biotechnology Letters,
vol. 27, no. 4, pp. 253â€“257, 2005.
[20] J.-A. Lee, H.-N. Sung, C.-H. Jeon et al., â€œA carbohydrate
fraction, AIP1 from Artemisia iwayomogi suppresses pul-
monary eosinophilia and Th2-type cytokine production in an
ovalbumin-induced allergic asthma. Down-regulation of TNF-
ğ›¼ expression in the lung,â€ International Immunopharmacology,
vol. 8, no. 1, pp. 117â€“125, 2008.
[21] J.-A. Lee, H.-N. Sung, C.-H. Jeon et al., â€œAIP1, a carbohydrate
fraction from Artemisia iwayomogi, modulates the functional
differentiation of bone marrow-derived dendritic cells,â€ Inter-
national Immunopharmacology, vol. 8, no. 4, pp. 534â€“541, 2008.
[22] S. Sato and P. F. Kador, â€œInhibition of aldehyde reductase by
aldose reductase inhibitors,â€ Biochemical Pharmacology, vol. 40,
no. 5, pp. 1033â€“1042, 1990.
[23] N. Matsuura, T. Aradate, C. Sasaki et al., â€œScreening system for
the Maillard reaction inhibitor from natural product extracts,â€
Journal of Health Science, vol. 48, no. 6, pp. 520â€“526, 2002.
[24] H. A. Jung, M. D. N. Islam, Y. S. Kwon et al., â€œExtraction and
identification of three major aldose reductase inhibitors from
Artemisia montana,â€ Food and Chemical Toxicology, vol. 49, no.
2, pp. 376â€“384, 2011.
[25] D. Osei-Safo, M. Chama, I. Addae-Mensah, and R. Waibel,
â€œHispidulin and other constituents of Scoparia dulcis Linn.,â€
Journal of Science and Technology, vol. 29, no. 2, pp. 7â€“15, 2009.
[26] V. MartÂ´Ä±nez, O. BarberaÂ´, J. SaÂ´nchez-Parareda, and J. Alberto
Marco, â€œPhenolic and acetylenic metabolites from Artemisia
assoana,â€ Phytochemistry, vol. 26, no. 9, pp. 2619â€“2624, 1987.
[27] J. A. Marco, O. BarberaÂ´, S. RodrÂ´Ä±guez, C. Domingo, and J. Adell,
â€œFlavonoids and other phenolics from Artemisia hispanica,â€
Phytochemistry, vol. 27, no. 10, pp. 3155â€“3159, 1988.
[28] D. Barron andR.K. Ibrahim, â€œOmbuin 3-sulphate from Flaveria
chloraefolia,â€ Phytochemistry, vol. 27, no. 7, pp. 2362â€“2363, 1988.
[29] J. D. Su, T. Osawa, S. Kawakishi, and M. Namki, â€œAntioxidative
flavonoids isolated fromOsbeckia chinensis L.,â€Agricultural and
Biological Chemistry, vol. 51, no. 10, pp. 2801â€“2803, 1987.
[30] F. Fathiazad, A. Delazar, R. Amiri, and S. D. Sarker, â€œExtraction
of flavonoids and quantification of rutin from waste Tabacco
leaves,â€ Iranian Journal of Pharmaceutical Research, vol. 3, pp.
222â€“227, 2006.
12 BioMed Research International
[31] N. J. Jun, K. C. Jang, S. C. Kim et al., â€œRadical scavenging activity
and content of cynarin (1,3-dicaffeoylquinic acid) in Artichoke
(Cynara scolymus L.),â€ Journal of Applied Biological Chemistry,
vol. 50, pp. 244â€“248, 2007.
[32] J. Chen, S. Mangelinckx, L. Ma, Z. Wang, W. Li, and N. De
Kimpe, â€œCaffeoylquinic acid derivatives isolated from the aerial
parts of Gynura divaricata and their yeast ğ›¼-glucosidase and
PTP1B inhibitory activity,â€ Fitoterapia, vol. 99, pp. 1â€“6, 2014.
[33] Y. Ding, C. Liang, S. Y. Yang, J. H. Kim, Y. M. Lee, and Y. H.
Kim, â€œIwayoside A, a new diterpene glycoside from Artemisia
iwayomogi kitamura that enhances IL-2 secretion,â€ Bulletin of
the Korean Chemical Society, vol. 31, no. 8, pp. 2422â€“2423, 2010.
[34] V. S. Chaturvedula, R. I. San Miguel, and I. Prakash, â€œChemical
constituents from the polar fraction of Rubus suavissimus,â€
Organic Chemistry: Current Research, vol. 1, article 101, 2011.
[35] Y. Chen, R. Zheng, Z. Jia, and Y. Ju, â€œFlavonoids as super-
oxide scavengers and antioxidants,â€ Free Radical Biology and
Medicine, vol. 9, no. 1, pp. 19â€“21, 1990.
[36] R. Pan, Y. Dai, X. Gao, and Y. Xia, â€œScopolin isolated from
Erycibe obtusifolia Benth stems suppresses adjuvant-induced
rat arthritis by inhibiting inflammation and angiogenesis,â€
International Immunopharmacology, vol. 9, no. 7-8, pp. 859â€“869,
2009.
[37] Y. Sun, X. Ma, and J. Liu, â€œCompounds from fraction with
cardiovascular activity of Chrysanthemum indicum,â€ China
Journal of Chinese MateriaMedica, vol. 37, no. 1, pp. 61â€“65, 2012.
[38] Y. S. Lee, Y.-H. Kang, J.-Y. Jung et al., â€œInhibitory constituents
of aldose reductase in the fruiting body of Phellinus linteus,â€
Biological and Pharmaceutical Bulletin, vol. 31, no. 4, pp. 765â€“
768, 2008.
[39] Y. Miyamae, M. Kurisu, J. Han, H. Isoda, and H. Shigemori,
â€œStructure-activity relationship of caffeoylquinic acids on the
accelerating activity on ATP production,â€ Chemical and Phar-
maceutical Bulletin, vol. 59, no. 4, pp. 502â€“507, 2011.
[40] H. A. Jung, J. J. Park, M. N. Islam et al., â€œInhibitory activity of
coumarins fromArtemisia capillaris against advanced glycation
endproduct formation,â€Archives of Pharmacal Research, vol. 35,
no. 6, pp. 1021â€“1035, 2012.
Submit your manuscripts at
https://www.hindawi.com
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
MEDIATORS
INFLAMMATION
of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Behavioural 
Neurology
Endocrinology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Disease Markers
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Oncology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Oxidative Medicine and 
Cellular Longevity
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
PPAR Research
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Obesity
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinsonâ€™s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
